Myriad Genetics Inc expected to post a loss of 8 cents a share - Earnings Preview

Myriad Genetics

04/11/2023 03:05

* Myriad Genetics Inc  MYGN.OQ   MYGN.O  is expected to show
a
rise in quarterly revenue when it reports  results 
    * The Salt Lake City Utah-based  company is expected to
report  a
14.6% increase in revenue to $179.232 million from $156.4
million a year ago, according to the mean estimate from 9
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Myriad Genetics Inc
is
for a loss of 8 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and 3 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Myriad
Genetics
Inc is $21.75​, above​ its last closing price of $17.02. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.09       -0.08      -0.08     Met     5.9
 Mar. 31 2023  -0.19       -0.19      -0.21     Missed  -8.6
 Dec. 31 2022  -0.15       -0.16      -0.12     Beat    26.5​
 Sep. 30 2022  -0.04       -0.06      -0.19     Missed  -216.7
 ​​Jun.        0.03        0.01       0.04      Beat    300
 30 2022                                                
 Mar. 31 2022  -0.06       -0.07      -0.03     Beat    55.3​
 Dec. 31 2021  -0.01       -0.02      -0.02     Met     14.3
 Sep. 30 2021  -0.01       -0.02      -0.02     Met     0
 This summary was machine generated November 4 at 03:05 GMT.  All
figures in US dollars  unless otherwise stated